410 related articles for article (PubMed ID: 33973371)
1. Risk of Hospitalization for Serious Infection After Initiation of Ustekinumab or Other Biologics in Patients With Psoriasis or Psoriatic Arthritis.
Jin Y; Lee H; Lee MP; Landon JE; Merola JF; Desai RJ; Kim SC
Arthritis Care Res (Hoboken); 2022 Nov; 74(11):1792-1805. PubMed ID: 33973371
[TBL] [Abstract][Full Text] [Related]
2. Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis.
Li X; Andersen KM; Chang HY; Curtis JR; Alexander GC
Ann Rheum Dis; 2020 Feb; 79(2):285-291. PubMed ID: 31672774
[TBL] [Abstract][Full Text] [Related]
3. Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis.
Yiu ZZN; Becher G; Kirby B; Laws P; Reynolds NJ; Smith CH; Warren RB; Griffiths CEM;
JAMA Dermatol; 2022 Oct; 158(10):1131-1141. PubMed ID: 35791876
[TBL] [Abstract][Full Text] [Related]
4. Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey.
Potenza MC; Peris K; Berardesca E; Bianchi L; Richetta A; Bernardini N; De Simone C; Teoli M; Zangrilli A; D'epiro S; Orsini D; Narcisi A; Chimenti S; Costanzo A
Dermatol Ther; 2018 Jan; 31(1):. PubMed ID: 29215183
[TBL] [Abstract][Full Text] [Related]
5. Association Between Biologics Use and Risk of Serious Infection in Patients With Psoriasis.
Penso L; Dray-Spira R; Weill A; Pina Vegas L; Zureik M; Sbidian E
JAMA Dermatol; 2021 Sep; 157(9):1056-1065. PubMed ID: 34287624
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
Kawalec P; Holko P; Moćko P; Pilc A
Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
[TBL] [Abstract][Full Text] [Related]
7. Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis.
McInnes IB; Nash P; Ritchlin C; Choy EH; Kanters S; Thom H; Gandhi K; Pricop L; Jugl SM
J Comp Eff Res; 2018 Nov; 7(11):1107-1123. PubMed ID: 30230361
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis.
Lu C; Wallace BI; Waljee AK; Fu W; Zhang Q; Liu Y
Semin Arthritis Rheum; 2019 Dec; 49(3):381-388. PubMed ID: 31272807
[TBL] [Abstract][Full Text] [Related]
9. Risk of Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis/Ankylosing Spondylitis Initiating Interleukin-17 Inhibitors: A Nationwide Population-Based Study Using the French National Health Data System.
Penso L; Bergqvist C; Meyer A; Herlemont P; Weill A; Zureik M; Dray-Spira R; Sbidian E
Arthritis Rheumatol; 2022 Feb; 74(2):244-252. PubMed ID: 34279061
[TBL] [Abstract][Full Text] [Related]
10. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis.
Acosta Felquer ML; LoGiudice L; Galimberti ML; Rosa J; Mazzuoccolo L; Soriano ER
Ann Rheum Dis; 2022 Jan; 81(1):74-79. PubMed ID: 34281904
[TBL] [Abstract][Full Text] [Related]
11. Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis.
Sauer BC; Teng CC; He T; Leng J; Lu CC; Walsh JA; Shah N; Harrison DJ; Tang DH; Cannon GW
J Med Econ; 2016; 19(1):34-43. PubMed ID: 26337538
[TBL] [Abstract][Full Text] [Related]
12. Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population.
Xu C; Teeple A; Wu B; Fitzgerald T; Feldman SR
J Dermatolog Treat; 2022 Jun; 33(4):2270-2277. PubMed ID: 34264149
[TBL] [Abstract][Full Text] [Related]
13. Risk of Infection in Children With Psoriasis Receiving Treatment With Ustekinumab, Etanercept, or Methotrexate Before and After Labeling Expansion.
Schneeweiss MC; Savage TJ; Wyss R; Jin Y; Schoder K; Merola JF; Sidbury R; Oduol T; Schneeweiss S; Glynn RJ
JAMA Dermatol; 2023 Mar; 159(3):289-298. PubMed ID: 36753234
[TBL] [Abstract][Full Text] [Related]
14. A Retrospective Cohort Study Comparing Utilization and Costs of Biologic Therapies and JAK Inhibitor Therapy Across Four Common Inflammatory Indications in Adult US Managed Care Patients.
Chastek B; White J; Van Voorhis D; Tang D; Stolshek BS
Adv Ther; 2016 Apr; 33(4):626-42. PubMed ID: 26970958
[TBL] [Abstract][Full Text] [Related]
15. Drug Survival of Biologics in Patients With Hidradenitis Suppurativa.
Ring HC; Maul JT; Yao Y; Wu JJ; Thyssen JP; Thomsen SF; Egeberg A
JAMA Dermatol; 2022 Feb; 158(2):184-188. PubMed ID: 34851360
[TBL] [Abstract][Full Text] [Related]
16. Elderly psoriatic patients under biological therapies: an Italian experience.
Ricceri F; Bardazzi F; Chiricozzi A; Dapavo P; Ferrara F; Mugheddu C; Romanelli M; Rongioletti F; Prignano F
J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):143-146. PubMed ID: 29906311
[TBL] [Abstract][Full Text] [Related]
17. Treatment persistence of biologics among patients with psoriatic arthritis.
Haddad A; Gazitt T; Feldhamer I; Feld J; Cohen AD; Lavi I; Tatour F; Bergman I; Zisman D
Arthritis Res Ther; 2021 Jan; 23(1):44. PubMed ID: 33514410
[TBL] [Abstract][Full Text] [Related]
18. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
Yiu ZZN; Mason KJ; Hampton PJ; Reynolds NJ; Smith CH; Lunt M; Griffiths CEM; Warren RB;
Br J Dermatol; 2020 Aug; 183(2):294-302. PubMed ID: 32124442
[TBL] [Abstract][Full Text] [Related]
19. Paradoxical onset of psoriatic arthritis during treatment with biologic agents for plaque psoriasis: a combined dermatology and rheumatology clinical study.
Napolitano M; Balato N; Caso F; Costa L; Megna M; Cirillo T; Balato A; Scarpa R
Clin Exp Rheumatol; 2017; 35(1):137-140. PubMed ID: 27749221
[TBL] [Abstract][Full Text] [Related]
20. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis.
Gisondi P; Bellinato F; Targher G; Idolazzi L; Girolomoni G
Ann Rheum Dis; 2022 Jan; 81(1):68-73. PubMed ID: 34144965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
